Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biohaven (BHVN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Biohaven between March 24, 2023 and May 14, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholde ...

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States ...

Summary of DiaMedica Therapeutics Conference Call Company and Industry - **Company**: DiaMedica Therapeutics - **Industry**: Biotechnology, specifically focusing on treatments for hypertensive disorders during pregnancy, such as preeclampsia Core Points and Arguments 1. **Clinical Trial Overview**: The call discussed the interim results from the Phase II Part 1a clinical trial of DM199 for preeclampsia, marking a critical milestone in addressing hypertensive disorders during pregnancy [3][6][34] 2. **Preeclampsia Statistics**: Preeclampsia affects over 10 million women globally each year, with nearly 200,000 cases in the US annually, particularly in early onset cases [5][6] 3. **Treatment Challenges**: Common treatments like ACE inhibitors and ARBs are contraindicated in pregnancy due to risks to the fetus, highlighting the need for safe alternatives like DM199 [6][26] 4. **Trial Objectives and Results**: - **Safety**: No placental transfer of DM199 was observed, confirming its safety profile [7][26] - **Blood Pressure Reduction**: Achieved significant reductions in both systolic (up to 35 mmHg) and diastolic blood pressure (up to 15 mmHg) at various time points [8][9][28] - **Intrauterine Artery Dilation**: A 13% reduction in the pulsatility index was noted, indicating improved placental perfusion [10][32] 5. **Future Directions**: Plans to expand research into fetal growth restriction, a related condition with no current FDA-approved treatments [6][35] Important but Overlooked Content 1. **Demographics of Participants**: The trial included women with severe hypertension, with a median gestation of around 37 weeks, primarily from black and mixed-race backgrounds [16][17] 2. **Cesarean Section Rates**: Approximately 70% of participants underwent cesarean sections due to the severity of their condition [20] 3. **Adverse Events**: While some expected complications occurred, the incidence was lower than anticipated, with no serious adverse events linked to DM199 [22][23] 4. **Pharmacokinetics and Future Dosing**: Ongoing analysis of pharmacokinetics will inform future dosing strategies, including potential titration based on individual patient needs [39][56] 5. **FDA Engagement**: Plans to submit data to the FDA later in the year for potential larger Phase II/III studies [69] This summary encapsulates the key findings and future directions discussed during the conference call, emphasizing the potential of DM199 as a breakthrough treatment for preeclampsia and related conditions.

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor’s four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased shares of Capricor between October 9, 2024 and July 10, 2025, and experienced ...

Core Points - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly providing misleading information regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] - The lawsuit claims that Capricor made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [2] - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [3] - Following the CRL announcement, Capricor's stock price dropped from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [4] Company Information - Capricor Therapeutics is involved in developing cell therapies, specifically targeting conditions like cardiomyopathy associated with DMD [2] - The company faced significant challenges with the FDA regarding its lead drug candidate, deramiocel, which has implications for its future development and market potential [3] Legal Context - The class action lawsuit allows investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, to seek recovery for losses incurred due to the alleged misleading statements [1][4] - Investors have until September 15, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]

Core Viewpoint - A securities fraud lawsuit has been filed against Capricor Therapeutics, Inc. and certain executives, alleging false statements regarding the safety and efficacy of their drug candidate, deramiocel, leading to significant investor losses [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Capricor Therapeutics misled investors about deramiocel's progress towards FDA approval while concealing adverse data from the Phase 2 HOPE-2 trial [2]. - Following the release of negative information, Capricor's stock price experienced significant declines: from $10.30 to $7.30 on May 5, 2025; from $11.94 to $8.26 on June 20, 2025; and from $11.40 to $7.64 after the FDA's Complete Response Letter on July 11, 2025 [2]. Group 2: Eligibility and Actions - Investors who purchased Capricor common stock between October 9, 2024, and July 10, 2025, and have incurred losses may be eligible to participate in the lawsuit [3]. - The deadline to seek appointment as lead plaintiff is September 15, 2025, and investors are encouraged to contact Block & Leviton for further information [4]. Group 3: Whistleblower Information - Individuals with non-public information about Capricor Therapeutics are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rocket-pharmaceuti ...

Calgary, Alberta--(Newsfile Corp. - July 17, 2025) - Further to the June 26 and July 9th press releases announcing the Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") non-brokered private placement of $2,500,000 and its oversubscription, the Company has accepted additional over-subscriptions totalling $500,000. The Company is amending its filing with the TSXV for a private placement for gross proceeds of up to $3,000,000. Purchasers have subscribed for Units at $0.10 ...

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell therapy, troculeucel, in Japan. Under Japan’s Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class forerunner for the treatment of several intractable neurodegenerative diseases. ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news that the company would shrink its workforce and pause several developmental projects as part of a restructuring plan. https://t.co/ETLDKPNLO8 ...